Bharat Biotech Ltd. valued its domestic coronavirus vaccine Covaxin at a price of 600 Rs per dose for states and 1200 Rs per dose for private hospitals. The vaccine, developed in collaboration with the government-funded Indian Council for Medical Research – National Institute of Virology, is more expensive than Covishield, the Indian version of AstraZeneca, co-invented by Oxford University and produced in India by the Serum Institute in India.
Purchase price for countries
- Covishield: Rs 400 per dose
- Covaxin: Rs 600 per dose
Sales price for private hospitals
- Covishield: 600 Rs per dose
- Covaxin: Rs 1,200 per dose
Each vaccine is a double dose.
These are the only two vaccines currently available in India and are procured by the central government which allocates them to states to be given to eligible citizens through government hospitals (free) and private hospitals (up to Rs 250 per dose).
Covaxin is an inactivated and highly purified vaccine and therefore its production is expensive, said Bharat Biotech in statement announcing prices on April 24th. All product development costs, production facilities and clinical trials were funded by the company using internal resources, the statement said.
Given global vaccine prices, we ensure that our vaccines are affordable compared to any other vaccine in the world, the Serum Institute said in its statement April 21.
Both are private companies, and the cost of vaccination is not publicly known, nor is their margin. But both are investing in capacity expansion to meet domestic and export demands.
It is estimated that Indians from 85 to 90 kroner can be vaccinated based on the new age criteria all those 18 years and more are now eligible.
For their vaccination India needs 170 – 180 crore doses. So far, 13.81 crore doses have been administered, according to Co-win. Only 2.10 crore of Indians received both doses.